Bristol Myers Squibb Company
NEWS
Paris-based Sanofi announced it is refocusing two of its international business units. The goal is to create more focus on mature markets and emerging markets.
Bristol-Myers Squibb announced that its Phase II clinical trial of BMS-986165 for moderate to severe plaque psoriasis hit its efficacy endpoints.
José Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center came under fire this weekend for his failure to disclose financial ties to various pharmaceutical companies when he published research papers in peer-reviewed journals.
Let’s take a look at who made a splash in the pharma and biotech world the past week.
Six months after launching with $60 million, Cambridge, Mass.-based Rheos Medicines has tapped Roche veteran Sanjay Keswani as the startup’s new chief executive officer.
There is a new player in the southern California biotech industry. New venture firm Westlake Village BioPartners launched with a $320 million fund and a leadership well familiar with the ins and outs of the biotech and pharma world.
Each year, Peter Drucker’s Drucker Institute generates its Management Top 250, evaluating companies based on what it calls five dimensions of corporate performance. Those five dimensions are Customer Satisfaction, Employee Engagement and Development, Innovation, Social Responsibility and Financial Strength.
Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let’s take a look.
Eli Lilly Oncology will have a new president at the helm of the division. Industry veteran Anne White has been tapped to lead the division beginning Sept. 1. She replaced Sue Mahoney whose last day with the company is today.
JOBS
IN THE PRESS